These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 27595248)

  • 41. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
    Montilla S; Marchesini G; Sammarco A; Trotta MP; Siviero PD; Tomino C; Melchiorri D; Pani L;
    Nutr Metab Cardiovasc Dis; 2014 Dec; 24(12):1346-53. PubMed ID: 25300980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA.
    Fofonka A; Ribeiro JP; Casali KR; Schaan BD
    Trials; 2014 Nov; 15():424. PubMed ID: 25366037
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes.
    Fonseca V; Schweizer A; Albrecht D; Baron MA; Chang I; Dejager S
    Diabetologia; 2007 Jun; 50(6):1148-55. PubMed ID: 17387446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Update: vildagliptin for the treatment of Type 2 diabetes.
    Garber AJ; Sharma MD
    Expert Opin Investig Drugs; 2008 Jan; 17(1):105-13. PubMed ID: 18095923
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.
    Ning G; Wang W; Li L; Ma J; Lv X; Yang M; Wang W; Woloschak M; Lukashevich V; Kothny W
    J Diabetes; 2016 May; 8(3):345-53. PubMed ID: 25929739
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): A randomized trial.
    Hong AR; Lee J; Ku EJ; Hwangbo Y; Kim KM; Moon JH; Choi SH; Jang HC; Lim S
    Diabetes Res Clin Pract; 2015 Jul; 109(1):141-8. PubMed ID: 26003889
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
    Cai L; Cai Y; Lu ZJ; Zhang Y; Liu P
    J Clin Pharm Ther; 2012 Aug; 37(4):386-98. PubMed ID: 22191695
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
    Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study.
    Blonde L; Dagogo-Jack S; Banerji MA; Pratley RE; Marcellari A; Braceras R; Purkayastha D; Baron M
    Diabetes Obes Metab; 2009 Oct; 11(10):978-86. PubMed ID: 19614942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes.
    Rosenstock J; Fitchet M
    Int J Clin Pract Suppl; 2008 Mar; (159):15-23. PubMed ID: 18269437
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring.
    He YL; Foteinos G; Neelakantham S; Mattapalli D; Kulmatycki K; Forst T; Taylor A
    Diabetes Obes Metab; 2013 Dec; 15(12):1111-9. PubMed ID: 23782529
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
    Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
    Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patient engagement impacts glycemic management with vildagliptin and vildagliptin/metformin (single pill) regimens in type 2 diabetes mellitus (the GLORIOUS study).
    Hermans M; Van Gaal L; Rézette I; Daci E; MacDonald K; Denhaerynck K; Vancayzeele S; De Meester L; Clemens A; Yee B; Abraham I
    Prim Care Diabetes; 2016 Dec; 10(6):425-433. PubMed ID: 27388795
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study).
    Suh S; Song SO; Kim JH; Cho H; Lee WJ; Lee BW
    J Diabetes Res; 2017; 2017():5282343. PubMed ID: 29057274
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Translating science into clinical practice: focus on vildagliptin in combination with metformin.
    Barnett AH
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():18-26. PubMed ID: 19385980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
    Matthews DR; Dejager S; Ahren B; Fonseca V; Ferrannini E; Couturier A; Foley JE; Zinman B
    Diabetes Obes Metab; 2010 Sep; 12(9):780-9. PubMed ID: 20649630
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE; Bhosekar V; Kawamori R
    Vasc Health Risk Manag; 2016; 12():9-12. PubMed ID: 26855580
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vildagliptin: a review of its use in type 2 diabetes mellitus.
    Keating GM
    Drugs; 2010 Nov; 70(16):2089-112. PubMed ID: 20964454
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
    Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
    Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus.
    Rosenstock J; Niggli M; Maldonado-Lutomirsky M
    Diabetes Obes Metab; 2009 Jun; 11(6):571-8. PubMed ID: 19383032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.